Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens
|
By LabMedica International staff writers Posted on 26 Aug 2014 |

Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).
Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).
The evaluation of lymphoid proliferations in these specimens can be particularly problematic, given the frequent presence of coexisting inflammatory conditions and the manner in which these specimens are processed.
Laboratory scientists at the Hospital of the University of Pennsylvania (Philadelphia, PA, USA) searched for all serous effusions specimens such as pleural fluid, peritoneal fluid, and pericardial fluid, and CSF specimens in which flow cytometry was performed, during the time period June 2008 to July 2012. Six-color flow cytometry was performed according to the manufacturer's protocol on a FACSCanto II flow cytometer (BD Biosystems; San Jose, CA, USA). A panel using different antibodies from Becton Dickinson Immunocytometry Systems, (San Jose, CA, USA) was utilized.
Flow cytometry was performed in 184 of 6,925 total cases (2.7% of all fluids). Flow cytometry was performed in 4.8% of pleural fluids (positive findings in 38%, negative in 40%, and atypical in 18%), 1.1% of peritoneal fluids (positive in 40%, negative in 50%, and atypical in 10%), 1.9% of pericardial fluids (positive in 67%, negative in 33%), and 1.9% of CSFs (positive in 23%, negative in 55%, atypical in 3%).
The authors concluded that atypical flow cytometry findings and atypical morphologic findings in the context of negative flow cytometry results led to the definitive diagnosis of a lymphoproliferative disorder in a significant number of cases when repeat procedures and ancillary studies were performed. Flow cytometry is especially suited for cells in fluid specimens, where aggregates of cells and extracellular matrix elements that may interfere with obtaining single cells for analysis are less prominent than in solid tissue specimens. In addition, it is well known to increase the sensitivity of detecting neoplastic populations of cells over morphology alone. The study was published in the August 2014 issue of the journal Diagnostic Cytopathology.
Related Links:
Hospital of the University of Pennsylvania
BD Biosystems
Becton Dickinson
The evaluation of lymphoid proliferations in these specimens can be particularly problematic, given the frequent presence of coexisting inflammatory conditions and the manner in which these specimens are processed.
Laboratory scientists at the Hospital of the University of Pennsylvania (Philadelphia, PA, USA) searched for all serous effusions specimens such as pleural fluid, peritoneal fluid, and pericardial fluid, and CSF specimens in which flow cytometry was performed, during the time period June 2008 to July 2012. Six-color flow cytometry was performed according to the manufacturer's protocol on a FACSCanto II flow cytometer (BD Biosystems; San Jose, CA, USA). A panel using different antibodies from Becton Dickinson Immunocytometry Systems, (San Jose, CA, USA) was utilized.
Flow cytometry was performed in 184 of 6,925 total cases (2.7% of all fluids). Flow cytometry was performed in 4.8% of pleural fluids (positive findings in 38%, negative in 40%, and atypical in 18%), 1.1% of peritoneal fluids (positive in 40%, negative in 50%, and atypical in 10%), 1.9% of pericardial fluids (positive in 67%, negative in 33%), and 1.9% of CSFs (positive in 23%, negative in 55%, atypical in 3%).
The authors concluded that atypical flow cytometry findings and atypical morphologic findings in the context of negative flow cytometry results led to the definitive diagnosis of a lymphoproliferative disorder in a significant number of cases when repeat procedures and ancillary studies were performed. Flow cytometry is especially suited for cells in fluid specimens, where aggregates of cells and extracellular matrix elements that may interfere with obtaining single cells for analysis are less prominent than in solid tissue specimens. In addition, it is well known to increase the sensitivity of detecting neoplastic populations of cells over morphology alone. The study was published in the August 2014 issue of the journal Diagnostic Cytopathology.
Related Links:
Hospital of the University of Pennsylvania
BD Biosystems
Becton Dickinson
Latest Immunology News
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Framework Guides Targeted Immunotherapy Selection in Liver Cancer
Primary liver cancer, encompassing hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), is the world’s third-leading cause of cancer-related death, responsible for about 830,000 deaths... Read more
Collaboration Brings Rapid At-Home STI Testing with Virtual Follow-Up
Sexually transmitted infections (STIs) are often asymptomatic, and reliance on clinic-based testing can delay diagnosis and treatment. More than one million curable infections are acquired daily worldwide... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreMicrobiology
view channel
mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
Central nervous system (CNS) infections such as encephalitis, ventriculitis, and brain abscess are among the most time-sensitive diagnostic challenges in neurology. Standard testing can return negative... Read moreRapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read morePathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







